Certified by Founder
Lodge
MBrace Therapeutics
start up
United States
- San Diego, California
- 15/11/2023
- Series B
- $85,000,000
MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.
- Industry Biotechnology Research
- Website https://mbracetrx.com/
- LinkedIn https://www.linkedin.com/company/mbrace-therapeutics/about/
Derapi | $7,000,000 | (Feb 4, 2026)
AIRRIVED | $6,100,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)
ecovia I bio | Undisclosed Amount | (Feb 4, 2026)
MaiaEdge | $20,000,000 | (Feb 4, 2026)
Mitra EV | $27,000,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
Graici | $7,500,000 | (Feb 4, 2026)
Prenosis | $20,000,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)